Northwire Canada EditionWednesday, July 15, 2026
Northwire
PTX 0.110 +0.0% VENT 0.160 +0.0% ANK 0.290 +0.0% ODV 3.37 +0.0% MINK 0.105 +0.0% ZEN 0.640 +0.0% LCE 0.240 +0.0% CBA 0.085 +0.0% SGU 0.040 +0.0% COSA 0.620 +0.0% DML 4.46 +0.0% MTT 0.150 +0.0% LME 0.185 +0.0% SVM 13.20 +0.0% NAU 1.87 +0.0% VTEN 0.580 +0.0% PTX 0.110 +0.0% VENT 0.160 +0.0% ANK 0.290 +0.0% ODV 3.37 +0.0% MINK 0.105 +0.0% ZEN 0.640 +0.0% LCE 0.240 +0.0% CBA 0.085 +0.0% SGU 0.040 +0.0% COSA 0.620 +0.0% DML 4.46 +0.0% MTT 0.150 +0.0% LME 0.185 +0.0% SVM 13.20 +0.0% NAU 1.87 +0.0% VTEN 0.580 +0.0%

← Back to our analysis

Original News Release

Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) FY26 Q1

Dallas, Texas--(Newsfile Corp. - August 14, 2025) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). During 1Q26, Burcon advanced meaningfully in its commercialization strategy. Within 90 days of commissioning its Galesburg facility, the Company achieved first commercial production of its next-generation Peazazz® C pea protein and debuted FavaPro fava protein. Initial shipments of Peazazz® C were completed during the quarter, supported by strong market reception and customer trials. Burcon also entered into a $6.8 million multi-year production agreement, underpinning its 2025 revenue target of $1-3 million. The Galesburg facility integrates Burcon's proprietary protein technologies, enabling scalable, versatile production across multiple plant-based proteins. This operational flexibility positions the Company to meet evolving customer needs quickly and with consistent quality, while unlocking a total addressable pea protein market estimated at US$215 million to US$392 million. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Achieved first commercial production and initial sales of Peazazz® C pea protein; launched FavaPro fava protein following strong customer response. Entered into $6.8M multi-year production agreement, providing baseline recurring revenue. Q1 FY26 revenue rose 44% YoY to $0.34M; startup costs at Galesburg facility impacted margins, with expenses now at "new normal" levels. Click image above to view full announcement. About Stonegate Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 [email protected] Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262569
View at source ↗